Cardiotoxicity of Immune Checkpoint Inhibitors

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression, cardiovascular toxicity can be a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Curr Oncol Rep
Egile Nagusiak: Patel, Rushin P., Parikh, Rohan, Gunturu, Krishna S., Tariq, Rana Zouveenoor, Dani, Sourbha S., Ganatra, Sarju, Nohria, Anju
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2021
Gaiak:
Cardio-oncology (EH Yang, Section Editor)
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088903/
https://ncbi.nlm.nih.gov/pubmed/33937956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11912-021-01070-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak